ReviewGalen medical journal2022
Review on Icariin as A Novel Medicaments to Confront Ovarian Cancer : Role of Icariin Against Ovarian Cancer.
Review in Galen medical journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ovarian cancer is described as one of the most common types of cancer and the leading cause of cancer-related deaths due to the high aggressiveness of this malignancy. However, the current therapeutically strategies failed to confront ovarian cancer or are accompanied by significant adverse effects leading to the recurrence of the disease and/or affecting the quality of life of survivors. On the other hand, ovarian cancer is recognized as a heterogenous disorder that is specified by alteration in a variety of molecular and cellular markers. Thereby, researchers are keen to find a novel therapeutical strategy representing high efficacy and safety, as well as be able to modulate altered biomolecules and signaling pathways. Icariin is a phytoestrogen with desired properties that are suggested for several chronic complications, particularly different types of cancer. The aim of the present study was to reveal the ameliorative characteristics of icariin and then discuss the antitumoral activities of this phytochemical against ovarian cancer with an emphasis on the modified molecular signaling pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.